Relapsing remitting multiple sclerosis (RRMS)

Active Ingredient: Tegomil fumarate

Indication for Tegomil fumarate

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Curative procedure

Tegomil fumarate is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).

For this indication, competent medicine agencies globally authorize below treatments:

174 mg twice daily for 7 days and thereafter 348 mg twice daily

For:

Dosage regimens

In case that patient age in years is ≥ 13

Oral, 174 milligrams tegomil fumarate, 2 times daily, over the duration of 7 days. Afterwards, oral, 348 milligrams tegomil fumarate, 2 times daily.

Detailed description

The starting dose is 174 mg twice a day. After 7 days, the dose should be increased to the recommended maintenance dose of 348 mg twice a day.

If a patient misses a dose, a double dose should not be taken. The patient may take the missed dose only if they leave 4 hours between doses. Otherwise, the patient should wait until the next scheduled dose.

Temporary dose reduction to 174 mg twice a day may reduce the occurrence of flushing and gastrointestinal adverse reactions. Within 1 month, the recommended maintenance dose of 348 mg twice a day should be resumed.

Tegomil fumarate should be taken with food. For those patients who may experience flushing or gastrointestinal adverse reactions, taking tegomil fumarate with food may improve tolerability.

Elderly

Clinical studies of tegomil fumarate had limited exposure to patients aged 55 years and above, and did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. Based on the mode of action of the active substance there are no theoretical reasons for any requirement for dose adjustments in the elderly.

Active ingredient

Tegomil fumarate

The mechanism by which tegomil fumarate exerts therapeutic effects in multiple sclerosis is not fully understood. Tegomil fumarate acts via the major active metabolite, monomethyl fumarate. Preclinical studies indicate that monomethyl fumarate pharmacodynamic responses appear to be primarily mediated through activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway.

Read more about Tegomil fumarate

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.